M.D. Anderson Cancer Center
To learn if imetelstat can help to control MDS/MPNs.
Primary Objectives * To determine the safety and tolerability of imetelstat in MDS/MPN * To assess efficacy (overall response (OR) rate) of imetelstat in MDS/MPN based on 2015 MDS/MPN IWG response criteria. * Incidence of AEs, maximum tolerated dose (MTD) and changes in clinical laboratory values. * Measures of efficacy: overall response rate (ORR) defined as sum of CR + complete cytogenetic remission + partial remission + marrow response + clinical benefit according to the IWG 2015 MDS/MPN response criteria.
Eligibility Criteria * Age ≥18 years as MF and CMML are very rare diseases in the pediatric population. * Diagnosis of MDS/MPN according to WHO including: 1. CMML-1 or CMML-2 with resistance or intolerance to hydroxyurea (if myeloproliferative subtype defined by WBC \>13x109/L) or with no response or intolerance to 4 cycles of azacitidine or decitabine or relapse or progression after any number of cycles. CMML-1 Participants with Hgb \<11g/dL, TSS score 20 or splenomegaly (defined as \>5cm under the lower costal margin by physical exam or \>12cm by imaging) in which hydroxyurea or HMA ther…
Given by IV
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.